Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sosei Co. Ltd.

Division of Sosei Co. Ltd./Sosei R&D Ltd./Sirus Pharmaceuticals Ltd.
www.sosei.com

Latest From Sosei Co. Ltd.

Deal Watch: Entasis, GARDP Partner On Novel Antibiotic For Drug-Resistant Gonorrhea

Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.

Deals M & A

$400m Heptares Acquisition To Drive Sosei’s R&D

Sosei is to pay up to $400 million to acquire the UK structure-based drug design specialist Heptares Therapeutics in a move that the Japanese firm hopes will bring fresh fuel to its R&D engine, complementing its existing nanotech and peptide technologies.

BioPharmaceutical Japan

Deals Shaping The Medical Industry, March 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January through February 2014.

BioPharmaceutical Medical Device

Acacia Pharma Raises $23.5 M Series B For Repurposing Drugs As Anti-Emetics

Other product candidates in the cancer supportive care sector being developed by the U.K. virtual biotech include a liquid formulation of a muscarinic agonist for dry mouth and a megestrol/formoterol combination therapy for muscle wasting.

BioPharmaceutical United Kingdom
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Sosei KK
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Sosei Co. Ltd.
  • Sosei Group Corp.
  • Senior Management
  • Shinichi Tamura, CEO
    Hidetoshi Torami, EVP, CFO
    Akinori Mochizuki, EVP, CSO
  • Contact Info
  • Sosei Co. Ltd.
    Phone: (0)3-5210-3290
    Kojimachi Tsuruya Hachiman Bldg. 5F
    2-4 Kojimachi
    Chiyoda-ku, Tokyo, 102-0083
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register